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A B S T R A C T
The recent revisions of the Organisation for Economic Co-operation and Development (OECD) genetic toxicology
test guidelines emphasize the importance of historical negative controls both for data quality and interpretation.
The goal of a HESI Genetic Toxicology Technical Committee (GTTC) workgroup was to collect data from par-
ticipating laboratories and to conduct a statistical analysis to understand and publish the range of values that are
normally seen in experienced laboratories using TK6 cells to conduct the in vitro micronucleus assay. Data from
negative control samples from in vitro micronucleus assays using TK6 cells from 13 laboratories were collected
using a standard collection form. Although in some cases statistically signiﬁcant diﬀerences can be seen within
laboratories for diﬀerent test conditions, they were very small. The mean incidence of micronucleated cells/1000
cells ranged from 3.2/1000 to 13.8/1000. These almost four-fold diﬀerences in micronucleus levels cannot be
explained by diﬀerences in scoring method, presence or absence of exogenous metabolic activation (S9), length
of treatment, presence or absence of cytochalasin B or diﬀerent solvents used as vehicles. The range of means
from the four laboratories using ﬂow cytometry methods (3.7-fold: 3.5–12.9 micronucleated cells/1000 cells)
was similar to that from the nine laboratories using other scoring methods (4.3-fold: 3.2–13.8 micronucleated
cells/1000 cells). No laboratory could be identiﬁed as an outlier or as showing unacceptably high variability.
Quality Control (QC) methods applied to analyse the intra-laboratory variability showed that there was
evidence of inter-experimental variability greater than would be expected by chance (i.e. over-dispersion).
However, in general, this was low.
This study demonstrates the value of QC methods in helping to analyse the reproducibility of results, building
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up a ‘normal’ range of values, and as an aid to identify variability within a laboratory in order to implement
processes to maintain and improve uniformity.
1. Introduction
The importance of historical control data was discussed by a
working group of the International Workshop on Genotoxicity Testing
(IWGT) at a meeting in Basel in 2009. Various recommendations were
made by the group for the use of historical control data [1]. They fo-
cused mainly on historical negative control data pointing to its use in
determining the acceptability of the experimental (concurrent) negative
control in the test and as evidence of a laboratory’s competency for
conducting an assay. The recommendations made in this IWGT paper
included: (1) the minimum sets of data needed for the creation of his-
torical control datasets, (2) consideration of the distribution of the data
rather than the simple ranges and (3) consideration of how such data
can assist in the interpretation of results.
Recent revisions of the Organisation for Economic Co-operation and
Development (OECD) Test Guidelines for the Testing of Chemicals now
include an increased emphasis on the use of historical negative control
data in the assessment of genotoxicity test results [2]. They include
recommendations on how to build an historical control database. For
example, the OECD TG 487 for the in vitro Mammalian Cell Micro-
nucleus Test [3] states that:
“When ﬁrst acquiring data for an historical negative control distribution,
concurrent negative controls should be consistent with published negative
control data where they exist. As more experimental data are added to
the control distribution, concurrent negative controls should ideally be
within the 95% control limits of that distribution. The laboratory’s his-
torical negative control database should initially be built with a minimum
of 10 experiments but would preferably consist of at least 20 experiments
conducted under comparable experimental conditions. Laboratories
should use quality control methods, such as control charts (e.g. C-charts
or X-bar charts), to identify how variable their positive and negative
control data are, and to show that the methodology is ‘under control’ in
their laboratory.”
The concurrent negative control data is used to assess whether the
experiment meets acceptability criteria based on whether the negative
control is considered to be acceptable for addition to the laboratory
historical control database. The criteria for the evaluation and inter-
pretation of results states that, in addition to an evaluation of the sta-
tistical signiﬁcance and dose response, at least one or more data points
must fall outside the distribution of the historical negative control. This
later criterion provides a means to assess the biological signiﬁcance of
the results.
The OECD test guidelines also provide guidance on the acceptance
criteria for inclusion of data into the historical negative control data-
base. They recommend comparisons of the test results with the histor-
ical negative control data as one of the three conditions necessary for a
deﬁnitive clear positive or negative result.
As a part of the deliberations during the last revision of the in vitro
test guidelines, the OECD collected a small amount of historical control
data for a number of in vivo and in vitro genotoxicity tests [4]. Data were
collected from a number of laboratories following a call from the OECD
for historical control data from diﬀerent tests including the in vitro
micronucleus test to help answer questions related to optimal cell
numbers and sample size issues, based upon the expected statistical
power and background incidence of genotoxic events in the negative
controls. During the course of the OECD revision discussions, a number
of limitations of this data set were identiﬁed including that reporting of
the data was non-standardized and some of the data sets were quite
variable. Furthermore, the analysis of those data sets showed what
appeared to be appreciable within and between laboratory variability
[4]. In view of these limitations, the HESI Genetic Toxicology Technical
Committee (GTTC) Data Interpretation Workgroup started a project to
collect and collate a set of data into a standardized database from well-
established laboratories.
To begin the project, the workgroup chose the in vitro micronucleus
test using the human lymphoblastic (B-cell) TK6 cells as the prototype
for collection of standardized control data and to develop methods to
assess these data. The TK6 cell line was chosen because of the poten-
tially large amount of relevant data that could be collected. The TK6
line is a standard and widely used cell line for the in vitro micronucleus
assay as it can be grown in suspension, does not need trypsinization, has
acceptable growth, is of human origin, has good karyotypic stability
and has retained its ‘wild-type’ p53 competency [5]. Lorge et al. [6]
provides a detailed description of the origin and establishment of the
TK6 cell line and the subsequent deposit of well characterized stocks
into cell banks. The paper provides guidelines for TK6 cell maintenance
and characteristics of the cells such as karyotype, p53 status, cell
growth and doubling times. The authors make recommendations for
TK6 cell culture conditions, preservation and quality checks for the cell
line. ‘Banks’ of the cells have been set up at the Japanese Collection of
Research Bioresources (JCRB) Cell Bank, Japan and subsequently at the
European Collection of Authenticated Cell Cultures (ECACC), UK.
The HESI GTTC Data Interpretation Workgroup put out calls in 2013
and 2014 for interested laboratories to submit data. A specially de-
signed Excel spreadsheet was created for the collection of the data in a
deﬁned and uniform way. The Excel spreadsheet was successfully
trialled by one of the participating laboratories before being sent out to
the other participants. Participating laboratories were asked to com-
plete the spreadsheet and provide answers to a series of speciﬁc ques-
tions developed by a Management Team on aspects of the conditions
used in their studies.
The goals of the project were: (1) to identify the range of data
collected by proﬁcient laboratories; (2) to see if any of the diﬀerent
‘factors’ in the conduct of studies aﬀect the variability; (3) to see
whether the historical negative control data could provide information
to make a recommendation of the appropriate number of experiments
needed to build a historical negative control database; and (4) to es-
tablish acceptable ranges of negative control database. This analysis
and publication are intended to provide high quality negative control
data for the in vitro micronucleus assay in TK6 cells carried out under
OECD guidelines. These will assist with the interpretation of test results
and with considerations of the type of data needed for the assessment
and application of expert judgement in the interpretation.
2. Materials and methods
Thirteen laboratories (four from the USA, three from Japan and six
from Europe) participated. Four (C, D, J, M) used ﬂow cytometry
methods while nine (A, B, E, F, G, H, I, K, L) used other scoring methods
including manual counting using light (4) or ﬂuorescent microscopes
(3), automated ﬂuorescence microscopy using the Cellomics ArrayScan®
VTi HCS Reader (1) and what was described as microscopy using image
analysis (1). No laboratory provided data using more than one method
on the same material. Data were collected from experiments carried out
between March 2003 and August 2014 although the time frame was, in
general, much narrower for the individual laboratory. For instance, one
laboratory has a range from 2003 to 2014 while others spanned less
than a year.
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2.1. Data collection and management
Data were collected using an Excel template with speciﬁc ﬁelds to
be populated (Table 1). In general, few problems were experienced in
the collection and management of the data. A small number of la-
boratories provided data in a non-standard format (these data were not
included because the data on individual experiments could not be ex-
tracted).
Results were obtained for three main types of experiments: short
treatment in the absence of S9 followed by a recovery period (−S9
short), short treatment in the presence of S9 followed by a recovery
period (+S9 short) and long treatment in the absence of S9 without
recovery (−S9 long). In most cases the duration of treatment is 3 h for
the short treatment and 24 h for the long treatment, and the most
commonly used recovery period is 24 h, but this did vary from la-
boratory to laboratory. A small amount of data were collected from
24 h treatment in the absence of S9 followed by a recovery period
longer than 24 h (−S9 longer). Two of the four laboratories (D, M)
using ﬂow cytometry methods only reported data from studies without
the addition of S9.
The data sets from all 13 laboratories (currently anonymized as A to
M) were broken down into 55 separate combinations of the various
conditions (e.g.±S9, time, scoring methods and vehicles). Most la-
boratories provided information at the individual replicate culture level
allowing assessment of the variability between replicate cultures within
a laboratory. Other laboratories reported just one replicate per ex-
periment. Two laboratories (F, I) pooled counts over two replicates and
consequently there was no opportunity to assess variability between
replicate cultures for these laboratories. Data on 4642 replicates were
provided by the 13 laboratories, mainly in the form of deﬁned multiples
of 1000 cells. Of these replicates, 1090 were from the four laboratories
using ﬂow cytometry. In some cases, there were a variable number of
replicates within a single experiment. In one experiment, Laboratory A
reported there were 25 replicates.
Data, in general, were reported in one of the following formats:
• Number of micronucleated cells for exactly 1000 (in a small number
of cases 2000) cells;
• Number of micronucleated cells from approximately 1000 cells;
• Number of micronucleated cells from a variable number of cells>
1000 (non-ﬂow cytometry methods);
• Number of micronucleated cells from a variable number of cells>
1000 (ﬂow cytometer method).
Diﬀerent solvents were used as vehicles including: water, dimethyl
sulfoxide (DMSO), phosphate buﬀered saline (PBS), saline, 10% Donor
Horse Serum − Roswell Park Memorial Institute (DHS-RPMI) and a
vehicle just described as “Medium”. The number of replicates/experi-
mental condition ranged from 2 to 795 (40–461 for the laboratories
using ﬂow cytometry). The number of cells/replicate scored by the nine
laboratories using non-ﬂow cytometry methods ranged from 1000
to> 2000 and 1238 to 21,772 for the four laboratories using ﬂow cy-
tometry methods.
No restrictions were placed upon the amount of data that could be
submitted except that laboratories were expected to have data from a
minimum of 20 experiments, which is often considered the lower limit
for the use of Quality Control methods [7]. In general, this was
achieved, although there were a number of cases where data were de-
rived from a smaller number of experiments because the number of
experiments carried out using particular combinations of conditions
(such as using a speciﬁc vehicle) was small. In all there were eight
combinations where data from only a small number of experiments (less
than 10 replicates including four combinations with just two replicates)
were available. These small numbers were accepted, however, because
these could be combined to provide higher numbers of replicates useful
in other analyses. However, combinations with just one experiment
with two replicates were not included in any of the analyses.
2.2. Statistical methods
Data were analysed using the statistical procedures available in
Minitab (Minitab 16 Statistical Software. Minitab, Inc., State College,
PA) and R [8]. Data from replicates of exactly 1000 cells were analysed
as integer counts. Data from replicates with variable numbers of cells
(especially much greater than 1000) were analysed as proportions of
micronucleated cells. In some analyses, proportions were multiplied by
1000 to give estimates of the number of micronucleated cells/1000 cells
scored.
The speciﬁc procedures were: one-way and nested analyses of var-
iances, tests for extra-binomial variation (i.e. Goodness of ﬁt to a
Poisson distribution), correlations between −S9 short and +S9 short
experiments (where applicable) and calculation of tolerance intervals.
A number of QC methods were used: C-Charts for Poisson counts, I-
Charts for individual replicate values of counts or proportions of mi-
cronucleated cells, p-Charts for proportions when the number of cells
counted diﬀered between replicates and X-bar Charts when there were
a number of replicates per experiment. Control charts are plots of data
collected over a period of time with decision lines added. They are long-
established and widely-used methods in industry to monitor the
variability of samples and to show that their processes are ‘under
control’ rather than drifting over time. There are a number of textbooks
describing these methods [7,9–11].
C-Charts are a version of the control chart speciﬁcally used for
count data. They are based upon the Poisson distribution but with a
constant denominator (n) and make use of the relationship in a Poisson
distribution between the mean and the variance. The upper and lower
control limits (UCL and LCL) are derived from the equation: cbar ±
3√cbar, where cbar is the estimate of the “long-term process mean”
derived from the initial development of the control chart. Fig. 1 is an
example of a C-Chart for Laboratory L (L1). C-Charts are presented here
with the mean of all replicates designated by a horizontal continuous
line. Hashed lines represent the mean±1SD,± 2SD and±3SD re-
spectively based upon the Poisson variance which is equivalent to the
Table 1
Speciﬁc information requested from participating laboratories.
General information
Laboratory
Guideline
Time period during which above data was collected
Cells
Cell line
Origin of the cell line
Maintenance of the cell line
Donor information
Stimulation conditions in case of lymphocytes
Treatment conditions
Treatment schedule short-term treatment +S9
Treatment schedule short-term treatment −S9
Treatment schedule long-term treatment −S9
Time of incubation with cytochalasin B
Cytochalasin B concentration
Solvent
Number of cultures per experiment
Metabolic activation
With or without
Origin
Concentration
Scoring
Method
Staining
Number of cells scored per treatment condition
Number of cells scored/culture
Scoring method
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mean. (Note that the Minitab package which produces the horizontal
lines on the ﬁgures refers to these lines as SL1, SL2, and SL3 respec-
tively.) The UCL and LCL are equivalent to the± 3SD lines and the
upper and lower warning limits (UWL and LWL) are equivalent to
the±2SD lines.
I-Charts are a “time-ordered sequence” plotting individual values
along the Y axis and the order of the individuals on the X axis. Fig. 2 is
an example of an I-Chart for Laboratory B (B1). X-bar Charts are plots
of the means of sets of replicates while p-Charts are plots of the pro-
portions of ‘events’ in a series of replicates where the cell numbers in
the replicate may diﬀer. Fig. 3 is an X-bar Chart for Laboratory C (C1)
and Fig. 4 is a p-Chart for Laboratory L (L2). Similar control and
warning limits to those derived for the C-charts can be produced for
these other QC charts.
In the QC charts, the points on the chart marked in grey are points
which have been ‘ﬂagged’ as ‘out of control’ based upon either the
Western Electric or Nelson rules which highlight points outside the UCL
or LCL or where various numbers of points are, for instance, in an in-
creasing progression. In the case of C- and p-Charts there are four tests
(Western Electric rules) while for the I- and X-Bar Charts there are eight
tests (Nelson rules) [10]. The scales for QC-charts are based upon the
number given to the replicate rather than dates so they do not reﬂect
the relative length of time the laboratory was undertaking the test.
3. Results
All the participating laboratories that provided data in the standard
format were diligent in their presentation of useable data. The data
from all of these laboratories (and all sets of conditions) were con-
sidered acceptable to include in the analyses. The quality of the data
was good.
Table 2 shows the mean and standard deviations (SD) for labora-
tories A to M for each of the 55 separate combinations of the var-
ious± S9, time, scoring methods and vehicles. The Supplementary
Results provide the summary results in diﬀerent formats to facilitate
comparisons.
Fig. 5 shows the mean and standard deviation for each combination
giving an indication of the relative variability in each set of replicates
whereas Fig. 6 shows the mean and its associated 95% conﬁdence in-
terval (CI) for each set giving an indication of the precision of the mean
values. The varying numbers of replicates is reﬂected in the widths of
the CIs (which provide an estimate of precision and are a function of
sqrt(n) in the calculation of the standard errors) so that those combi-
nations with very small n’s will have very wide CIs (note that in Table 2,
21 combinations had less than 20 replicates and 12 of these had 10 or
less replicates.) Non-overlapping CIs between laboratories with small
diﬀerences in means can be identiﬁed when these CIs are based upon a
large number of replicates (n); however, this is more a consequence of
these large n’s than representing biologically important diﬀerences.
Fig. 1. Example of a C-Chart for Laboratory L (L1).
Plot of counts of micronucleted cells from 175 experiments (−S9 short,
most with single replicate). Lack of connecting lines between points in
places relate to cases where particular combination was not included in
experiment.
Fig. 2. Example of an I-Chart for Laboratory B (B1).
Plot of counts of micronucleated cells from 12 experiments where 2000
cells were scored from each of two replicates.
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Fig. 5 also shows the ‘breakdown’ of the means by scoring method
with the ﬂow cytometry-based methods being shown in grey and the
other methods shown in black. Fig. 6 shows the breakdown based upon
the presence or absence of S9 (+S9 or −S9). The mean values for the
55 combinations were 7.06/1000 (SD 2.35/1000). Fig. 7 shows the
distribution of the means. There was no evidence of any diﬀerences in
the means of the ﬂow cytometry scoring laboratories compared with the
others, or between the presence and absence of S9 (results shown in
Supplementary Results).
Table 2 and Fig. 7 show that there was inter-laboratory variability in
estimates of micronucleated cells/1000 cells, with statistically sig-
niﬁcant (P < 0.001) greater variability between laboratories than
within based upon analyses of variance (results shown in Supplemen-
tary Results). However, there were no dramatic outliers. The mean
values for the 55 combinations ranged from 3.20/1000 for one com-
bination for Laboratory E to 13.83/1000 for one combination for La-
boratory K. In general, mean values for diﬀerent conditions were si-
milar within the same laboratory. An exception was Laboratory K
where the mean values from the ﬁve conditions ranged from 5.50/1000
to 13.83/1000. There were variable levels of intra-laboratory varia-
bility in the participating laboratories. Laboratory J showed appreci-
ably more variability than the other laboratories. All the laboratories
had mean scores of over 3.2/1000. Based upon a Poisson distribution
very few zero values would be expected with these levels of mean
scores. In fact, only two replicates (from E6 and G4) had zero counts.
Formal comparison between the laboratories using ﬂow cytometry
or other scoring methods was diﬃcult to assess because of the small
number of laboratories participating. Furthermore, no laboratory used
more than one method for the same series of experiments. There was
some overlap between the results from the ﬂow cytometry and the
other scoring methods. The ranges seen with the ﬂow cytometry-based
scoring (3.50/1000 to 12.88/1000) and the other scoring methods
(3.20/1000 to 13.83/1000) were comparable.
Representative examples of some of the QC graphs are shown in the
Supplementary Results section. Examination of the QC plots indicates
that, although there are some diﬀerences in the means and the varia-
bility, each laboratory has a distinctive pattern of results with a clear
and relatively narrow range of negative control/baseline values.
Some of these graphs illustrate ‘interesting’ aspects of the data
provided. The degree to which the intra-laboratory variability diﬀered
between laboratories can be seen from these charts such as those cases
where there seemed to be ‘shifts’ or ‘step-changes’ in mean levels in the
numbers of micronucleated cells (for example, Laboratories J and M). A
more complete set of analyses is provided in the Supplementary Results.
In several laboratories, some of the early replicates in the QC charts are
outside the control limits which suggest increased variability in the
early stages of the development of the assay in the laboratory which
may be expected.
Fig. 3. Example of an X-bar Chart for Laboratory C (C1).
Plot of mean counts of micronucleated cells from 20 experiments where
10000 cells were scored from each of two replicates (scoring by ﬂow
cytometer).
Fig. 4. Example of a p-chart for Laboratory L (L2).
Plot of proportion of counts of micronucleted cells from 175 experiments
(+S9 short, most with single replicate). Lack of connecting lines between
points in places relate to cases where particular combination was not in-
cluded in experiment. Numerical values linked to grey points relate to
points ‘ﬂagged up’ by Western Electric rules (see text).
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4. Discussion
4.1. Study design, data collection and analysis
The role of historical control data is becoming more important in
the analysis and interpretation of genetic toxicology tests as illustrated
by the latest revision of the OECD Test Guidelines [2]. Historical
control data can be useful provided the data chosen are comparable
with the study being investigated (i.e. obtained under the same ex-
perimental conditions). They can also provide information on diﬀer-
ences detected between negative control groups which have either re-
ceived a vehicle or not (i.e. absolute negative controls) in those cases
where a less commonly used vehicle is chosen. It should, though, be
stressed that, in any discussion of historical control data, comparisons
Table 2
Means and SDs of micronucleated cells/1000 cells for 55 combinations for 13 laboratories (split between scoring methods).
Row Lab Comb N Mean SD Meth Vehicle Cyto-B S9 Time
1 A A1 14 7.43 3.86 M DMSO Y +S9 Short
2 A A2 10 8.30 4.47 M Water Y −S9 Short
3 A A3 2 6.50 0.71 M Water Y +S9 Short
4 A A4 22 10.59 3.63 M Water Y −S9 Long
5 A A5 24 8.58 4.65 M Water Y −S9 Longer
6 A A6 59 8.32 3.31 M DMSO N −S9 Short
7 A A7 72 8.15 3.91 M DMSO N +S9 Short
8 A A8 48 7.31 3.08 M DMSO N −S9 Long
9 A A9 8 7.25 2.25 M Water N −S9 Short
10 A A10 26 7.58 3.58 M Water N −S9 Long
11 A A11 22 7.96 3.34 M Water N −S9 Longer
12 B B1 24 7.65 2.08 M DMSO N −S9 Short
13 B B2 24 7.21 1.89 M DMSO N +S9 Short
14 B B3 24 7.88 2.51 M DMSO N −S9 Long
19 E E1 21 4.76 1.84 M Water N −S9 Short
20 E E2 19 3.90 1.29 M Water N +S9 Short
21 E E3 21 4.14 1.68 M Water N −S9 Long
22 E E4 27 4.70 1.66 M DMSO N −S9 Short
23 E E5 32 4.63 2.17 M DMSO N +S9 Short
24 E E6 39 3.62 1.93 M DMSO N −S9 Long
25 E E7 6 4.17 1.47 M Medium N −S9 Short
26 E E8 11 4.09 1.58 M Medium N +S9 Short
27 E E9 10 3.20 1.62 M Medium N −S9 Long
28 F F1 26 7.77 2.30 M 10%DHS-RPMI Y −S9 Short
29 F F2 12 6.14 1.71 M 10%DHS-RPMI Y +S9 Short
30 F F3 16 6.88 1.48 M 10%DHS-RPMI Y −S9 Long
31 F F4 2 9.72 6.68 M 10%DHS-RPMI Y −S9 Longer
32 G G1 20 7.30 2.56 M Saline Y −S9 Short
33 G G2 20 6.60 3.36 M Saline Y +S9 Short
34 G G3 14 5.29 3.60 M Saline Y −S9 Long
35 G G4 14 3.50 2.03 M Water Y −S9 Long
36 G G5 2 5.00 1.41 M DMSO Y −S9 Short
37 G G6 6 5.83 2.86 M DMSO Y +S9 Short
38 G G7 10 4.80 2.35 M DMSO Y −S9 Long
39 H H1 10 10.20 2.32 M DMSO N −S9 Short
40 H H2 117 9.04 2.75 M DMSO N +S9 Short
41 H H3 132 8.83 2.58 M DMSO N −S9 Long
42 I I1 623 9.26 2.16 M DMSO N −S9 Short
43 I I2 795 9.01 1.99 M DMSO N +S9 Short
44 I I3 765 8.69 1.92 M DMSO N −S9 Long
47 K K1 11 9.73 5.39 M DMSO N −S9 Short
48 K K2 28 9.86 7.03 M DMSO N −S9 Long
49 K K3 2 5.50 0.00 M DMSO N −S9 Longer
50 K K4 12 13.83 6.18 M Water N −S9 Long
51 K K5 4 5.75 3.10 M Water N −S9 Longer
52 L L1 117 8.23 3.15 M DMSO N −S9 Short
53 L L2 111 7.96 3.43 M DMSO N +S9 Short
54 L L3 118 8.80 3.28 M DMSO N −S9 Long
15 C C1 40 5.68 1.42 F DMSO N −S9 Short
16 C C2 44 7.46 2.60 F PBS N −S9 Short
17 C C3 42 6.16 1.99 F DMSO N +S9 Short
18 D D1 461 3.54 1.59 F DMSO Y −S9 Long
45 J J1 135 12.88 8.68 F DMSO N +S9 Short
46 J J2 251 7.88 4.82 F DMSO N −S9 Long
55 M M1 212 3.50 1.49 F DMSO N −S9 Long
Comb: Combination; N: number of replicates; SD, Standard Deviation; Meth: scoring method F (Flow cytometry); M (other methods); S9;−S9 or +S9; Time; short, long, longer. (See text
for more details of combinations).
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of test groups with the concurrent negative control group is the primary
consideration in testing for genotoxicity testing.
The current GTTC workgroup analysis of negative control data from
13 laboratories using the TK6 cell line micronucleus assay provides
important guidance values to improve the use of negative control data
both for quality control and in the interpretation of test results. This
assay and cell line was selected based on the likelihood that a suﬃcient
amount of data could be obtained from a relatively small group of
proﬁcient laboratories using well-deﬁned protocols from companies
and institutes in the ﬁeld. Some eﬀort was put into securing their
participation. The number of participating laboratories is considered
adequate and is comparable with other inter-laboratory comparison
studies. It was a requirement for participation that laboratories were
able to provide data from at least 20 individual experiments. The results
can, therefore, be considered a ‘best case scenario’ and a successful
‘proof of principle’ for further studies.
The selected laboratories included those using accepted methods of
scoring including ﬂow cytometry, light and ﬂuorescence microscopy.
[6]. Details of the characteristics of the TK6 cell line and re-
commendations for its maintenance can be found in another HESI GTTC
Fig. 5. Means and SD of 55 combinations: Grey: Flow; Black: Other
Methods.
Fig. 6. Means and 95%CI of 55 combinations: Grey: −S9; Black: +S9.
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paper [6]. Many laboratories (10) reported that they obtained their cell
lines from ATCC (American Type Culture Collection). No information
on the original donors was provided by any laboratory.
The data collected in this study were analysed by standard statistical
methods and using QC tools which are widely used in industry to
monitor processes and to ensure maintenance of quality control. This is
now recommended by the OECD test guidelines. Although the length of
data collection varied over time (range six months to 10 years) these
data show that QC methods have a role in improving a laboratory’s
performance and that a further reduction of intra-laboratory variability
is feasible. It is not known whether laboratories provided data from all
their experiments or whether those experiments that were considered to
have failed to meet the laboratory’s own acceptance criteria were ex-
cluded from the datasets. Laboratories may vary in the degree to which
they ‘self-edited’ their datasets. If this was the case, then such a la-
boratory might be expected to report less variability than actually oc-
curred.
One of the complications in building up negative control databases
is whether data can be combined across the diﬀerent conditions to in-
crease the number of replicates and achieve the ‘rule of thumb’ of 20
experiments for QC methods. In most cases here, there were no ap-
preciable diﬀerences between the diﬀerent sets of replicates within a
laboratory. One diﬃculty is developing the database so that the QC
charts can be based upon the order the experiments were conducted in
(i.e. in a time-ordered format). In practice, it should be the responsi-
bility of the laboratory to make the case for combining the results and
doing this in a transparent way so that others can judge whether this is
appropriate.
One of the complexities of cross laboratory comparisons is the
standardization of the endpoints. Diﬀerent laboratories use diﬀerent
denominators (e.g. 1000, 2000 or variable numbers of cells.) Results
presented in the form of the number of micronucleated cells/cells
scored expressed as proportions are also common; sometimes with
diﬀerent numbers of cells per replicate. In this case the precision of the
Fig. 7. Distribution of the mean micronucleated
cells/1000 cells from the 55 combinations from the
13 participating laboratories.
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estimate of the mean for those conditions will vary from combination to
combination. Estimates derived from ﬂow cytometry are likely to be
more precise than those from manual scoring due to the increased
number of cells scored.
4.2. Between laboratory variability
The between laboratory variability is signiﬁcantly greater than the
within laboratory variability (P < 0.001 in an analysis of variance)
(Figs. 8 and 9). The percentage variability in the replicate counts ex-
plained by the between laboratories component was nearly 70%. Less
than 2% of the variability can be explained by including other factors in
a multiple regression analysis. The inter-laboratory variability cannot
be explained by the variables outlined in the methods section. There
does not seem to be any large or systematic eﬀects of experimental
conditions such as choice of vehicle, short or long treatment and re-
covery times or the presence or absence of cytochalasin B (three la-
boratories reported using cytochalasin B with their TK6 cells) on the
size of the means within and between the laboratories. Some inter-la-
boratory variability might be due to variables such as staining methods
(seven laboratories used acridine orange and two Giemsa stains), types
of visualization and scoring methods which diﬀered between labora-
tories. Direct comparisons is diﬃcult because of the relatively small
numbers of laboratories using each method. However, there was no
indication that these studies gave unusual or very diﬀerent results.
None of the variability that might be associated with these diﬀerent
experimental conditions exceeded that which could be due to other
uncontrolled factors. This indicates that factors which diﬀer between
laboratories in the protocol have not been identiﬁed and contribute to
the variability.
One extra source of variability between laboratories is the range of
the lengths of the treatment and recovery time. Treatment times de-
ﬁned by the laboratories ranged from 3 to 4 h with recovery times
varying from 21 to 40 h for both with and without S9 mix. The corre-
sponding times for the −S9 long protocol were 24–30 h with no re-
covery time; the −S9 longer protocols had 24–48 h treatment times.
These are the nominal times but variability may have been introduced if
the actual times that the cells experienced in treatments in the la-
boratories diﬀered somewhat from these.
Another explanation for the inter-laboratory variability could be the
sources of the cell lines. Most of the laboratories reported that their cell
lines originated from a reputable source, the ATCC. Lorge et al. describe
the need for well-standardized cell lines [6] and noted that diﬀerent
results can arise, even when experienced laboratories test a speciﬁc
chemical using batches of cells believed to have been derived from the
same origin [5]. Other possible sources of variability (heterogeneity)
between laboratories could include passage number, the original donors
and pooling cells.
4.3. Within laboratory variability
In those cases where it was possible to assess intra-laboratory
variability, this was low with little diﬀerence between the diﬀerent
study designs (−S9 short, +S9 short and −S9 long). In some cases
(where this was testable), there was some statistically signiﬁcant
variability between experiments within a laboratory. In these cases,
however, the mean diﬀerences were small and unlikely to be biologi-
cally important to the extent that they would impact the results of
conducting the micronucleus test.
Heterogeneity within a laboratory can be introduced by diﬀerent
scorers over time. A number of laboratories noted, however, that all the
scoring had been done by a single scorer, in some cases, blinded to the
treatment groups, which would also blind the scorer to the negative
controls.
In nearly all laboratories there was evidence of over-dispersion
where the between replicates variability was greater than what would
be expected just by sampling error. This indicates that there are vari-
ables other that those recorded in the study that can lead to the
variability in the results. Over-dispersion is an issue in the derivation of
control limits. The relationship between the mean and SD of counts
provides some indication of the degree of over-dispersion. The labora-
tories varied with respect to the uniformity of their results. Laboratory
L, for instance, reported results from 346 replicates but showed only the
occasional values with extreme variability in the QC charts. Laboratory
D, on the other hand, with 461 replicates showed an appreciable
number of replicates over the UCL (see Supplementary Results, Figs.
S59 and S24).
The signiﬁcant variability between experiments within laboratories
also suggests that it should be possible to achieve a further reduction in
the degree of inter-replicate variability. To achieve this, a laboratory
would need to check its procedures to see whether there were potential
aspects of its protocol that might introduce variability between re-
plicates and between experiments. Ryan [7] discusses, in general, ap-
proaches that can be used to do this.
One possible innovation for the counts obtained from the ﬂow cy-
tometry method would be a check that the proportion of micronuclei in
each 1000 cells scored consecutively conforms to a Poisson distribution.
This does not have to be done but it would provide a QC check on the
Fig. 8. Box plots of the distribution of the micronucleated cells/1000 cells
from the 13 participating laboratories.
Shaded box plot indicate laboratories using ﬂow cytometry, clear box plots
indicate laboratories using other counting methods. Asterisks indicate
potential outliers.
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possibility that there was variability in the selection of cells over the
longer run of sampling.
4.4. QC charts and acceptable ranges
Counts on the same number of cells are readily analysed using
methods based upon the Poisson distribution. C-Charts have the ad-
vantage that the width of the control limits depends upon the theore-
tical relationship between the mean and the variance of the Poisson
distribution and it is possible to derive Poisson-based control limits.
These allow a degree of visual representation of how much over-dis-
persion there was within the laboratories.
The control limits, therefore, represent the ‘pure error’ associated
with the endpoint and what can be achieved in the absence of inter-
replicate or inter-experiment variability. This can, therefore, represent
the ‘normal’, baseline, or irreducible variability associated with the
endpoint. Counts that fall outside these limits either represent very rare
random events or, more likely, the eﬀect of some uncontrolled factor.
Attempts to detect shifts in the mean within this ‘normal range’ would
require large experiments to have suﬃcient power.
Based upon these results, it can be argued that an acceptable level of
variability for the background control incidence of micronuclei would
be one that fell within the control limits such as the±2SD range (i.e.
the LWL and UWL) provided that the dataset does not show excessive
variability. Obviously the mean level within a speciﬁc laboratory aﬀects
the size of eﬀect detectable and the design of a study with the power to
detect a doubling over the negative control level.
In the combined groups there were ﬁve cases (A, E, G, K and L)
where the calculated LCL was ‘below zero’. This means that there is no
lower value that would be outside the limits. However, in all these cases
the calculated ‘negative’ LCLs values were just below zero indicating
that zero values, while not ‘triggering a warning’ were close to the LCL.
The range of estimates of micronucleated cells/1000 cells across all
the 55 combinations in 13 laboratories was from 3.2 to 13.8/1000 cells.
Only four of the combinations had means outside the range 3.5/1000
and 10.6/1000. This range might be considered an indicator of accep-
table performance if accompanied by evidence that the level of intra-
laboratory variability is satisfactory. A slightly larger range is obtained
from the mean ± 2SD of the overall mean of the 55 combinations:
7.06 (2.37–11.76) or from the overall means of the 13 laboratories
across combinations: 7.48 (3.45–11.51). These ranges, calculated as the
mean±2SD, could, therefore, be considered as acceptable.
Combinations J1 and K4 fall outside these ranges showing appreciable
variability and K4 had a small numbers of replicates. By excluding these
two combinations, an acceptable range from to 3.20 to 10.59 was
achieved. Laboratories with means falling outside this range should
review their technical procedures.
The range of values, although wide, seems an acceptable range and,
therefore, advice could be given that laboratories carrying out the assay
should be able to show both that their mean value lies within this range
and show evidence of acceptable level of within-laboratory variability
around their speciﬁc mean as demonstrated by QC methodology.
Therefore, each laboratory should be able to set its own acceptable
range which should be narrower than one based solely upon the spread
of the laboratories’ overall means in this study.
4.5. Other data in the literature
The values reported here are broadly in line with those reported by
other investigators but on a much larger set of data. Lorge et al. [6]
report a value of 10.2 ± 4.8 scored on 1000 cells (without cytocha-
lasin B) based upon data from Honma and Hayashi [12] and note “…
that these ranges reﬂect values from experienced laboratories handling
the cells under rather standardized procedures. They should be taken
seriously as recommendations for acceptable values, but not as strict
speciﬁcations for exact values for other laboratories and have no reg-
ulatory status.”
Zhang et al. [13] published negative control incidences of between
6 and 15 mnt/1000 cells (based upon approximately 13 experiments
with a single replicate per experiment). Honma and Hayashi [12] re-
ported background negative control data in TK6 cells following a 4 h
treatment +48 h recovery protocol without S9 mix and presumably
without cytochalasin B (as there was no mention of cytochalasin B in
their paper). They reported incidences of a mean of 10.2/1000 cells (SD
4.8/1000 cells). This mean was presumably based upon the negative
control data from the 25 participating laboratories which tested 14
chemicals in their study. From their Fig. 3, the range of the values is
from just over 0/1000 to approximately 25/1000 with a median of
about 10/1000 (the values in their Fig. 3 do not seem, however, to
relate to the results of the 30 experiments shown in their Table III
where the range appears to be from 4 to 16 micronucleated cells/1000
cells). The vehicle used was either physiological saline or DMSO. A
single negative control culture appears to have been scored in each
experiment with at least 1000 cells scored for micronuclei (the range of
values reported, therefore, in eﬀect, includes both a between laboratory
and a within laboratory component).
In the OECD report [4], ﬁve laboratories (with between 39 and 198
replicates) described micronuclei incidences with a range of from 4.2/
Fig. 9. Mean and 95% CI for the mean micronucleated cells/1000 cells
from the 13 participating laboratories.
Open circle indicates laboratory used ﬂow cytometry and ﬁlled circle in-
dicates laboratory using other counting methods.
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1000 to 11.3/1000. Two of the laboratories indicated that they had
used cytochalasin-B and reported micronuclei frequencies of 4.2/1000
and 7.1/1000 cells.
Background levels of micronucleated TK6 cells in the presence or
absence of cytochalasin B can also be found in the literature. Fellows
and O’Donovan [14] reported, in a non-cytokinesis blocked assay with
S9 mix (i.e. no cytochalasin B block), micronuclei frequencies of 7.5/
1000 cells and 8.3/1000 cells in negative control TK6 cultures after 24-
and 48-h ‘treatments’ respectively. Elhajouji [15] described negative
control incidences (in Tables 1–4 of the paper) of 7–20.5/1000 cells in
human TK6 cells in the presence and absence of cytochalasin B. These
incidences appear to be based upon a single replicate negative control
in each experiment. Fowler et al. [16] indicated negative control in-
cidences based upon quadruplicate cultures (in Tables 1–3 of their
paper) of 4.5–9.5/1000 cells in human TK6 cells in the presence and
absence of cytochalasin B.
In conclusion, this study has identiﬁed the range of results collected
by 13 proﬁcient laboratories in conducting the in vitro micronucleus
assay using TK6 cells. In addition, it demonstrates, that the variability
between laboratories does not appear to be due to a number of diﬀer-
ences in how the data were produced. This study supports the need for
data to be produced from about 20 experiments to create a negative
control database, it also provided evidence to justify the OECD guide-
line recommendation that at least 2000 cells (from two cultures) per
concentration should be scored in order to provide an acceptable range
for historical control databases. Furthermore each laboratory should be
able to set its own acceptable range which should be narrower than one
based solely upon the spread of the laboratories’ overall means in this
study.
Acknowledgements
The authors wish to thank the participating laboratories and their
staﬀ who provided data: AstraZeneca, BSRC, Canon Inc, Covance,
Janssen A, Janssen B, Litron, Lundbeck, NCTR, Novartis, Pﬁzer, Sanoﬁ,
and Takeda. The authors also thank the HESI GTTC and the Data
Interpretation Workgroup for intellectual and ﬁnancial support. This
research did not receive any speciﬁc grant from funding agencies in the
public, commercial, or not-for-proﬁt sectors.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.mrgentox.2017.10.006.
References
[1] M. Hayashi, K. Dearﬁeld, P. Kasper, D. Lovell, H.J. Martus, V. Thybaud,
Compilation and use of genetic toxicity historical control data, Mutat. Res. 723
(2011) 87–90.
[2] OECD, Guidance Document on Revisions to OECD Genetic Toxicology Test
Guidelines, Genetic Toxicology Guidance Document: Second Commenting Round.
Nov 30, 2015, https://www.oecd.org/env/ehs/testing/Draft%20Guidance
%20Document%20on%20OECD%20Genetic%20Toxicology%20Test
%20Guidelines.pdf.
[3] OECD, Guideline for the testing of chemicals, Test No. 487, In vitro mammalian cell
micronucleus Test, 2016. http://www.oecd-ilibrary.org/environment/test-no-487-
in-vitro-mammalian-cell-micronucleus-test_9789264264861-en.
[4] OECD, Environment, Health and Safety Publications, Series on Testing and
Assessment, No. 198, Report on statistical issues related to OECD test guidelines
(TGs) on genotoxicity, ENV/JM/MONO(2014)12, 2014. http://www.oecd.org/
oﬃcialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2014)12&
doclanguage=en.
[5] S. Pfuhler, M. Fellows, J. van Benthem, R. Corvi, R. Curren, K. Dearﬁeld, P. Fowler,
R. Frotschl, A. Elhajouji, L. Le Hegarat, T. Kasamatsu, H. Kojima, G. Ouedraogo,
A. Scott, G. Speit, In vitro genotoxicity test approaches with better predictivity:
summary of an IWGT workshop, Mutat. Res. 723 (2011) 101–107.
[6] E. Lorge, M.M. Moore, J. Clements, M. O’Donovan, M.D. Fellows, M. Honma,
A. Kohara, S. Galloway, M.J. Armstrong, V. Thybaud, B. Gollapudi, M.J. Aardema,
J.Y. Tanir, Standardized cell sources and recommendations for good cell culture
practices in genotoxicity testing, Mutat. Res. 809 (2016) 1–15.
[7] T.P. Ryan, Statistical Methods for Quality Improvement, John Wiley & Sons, Inc.,
2011.
[8] RCore Team, R: A Language and Environment for Statistical Computing, R
Foundation for Statistical Computing, Vienna, Austria, 2014.
[9] G.R. Henderson, Introduction, Six Sigma Quality Improvement with Minitab, John
Wiley & Sons, Ltd, 2011, pp. 1–11.
[10] D. Montgomery, Introduction to Statistical Quality Control, 6th edition, John Wiley
& Sons, Inc, Hoboken, New Jersey, 2009.
[11] E. Mullins, Statistics for the Quality Control Chemistry Laboratory, The Royal
Society of Chemistry, Cambridge, 2003 ISBN 0-85404-671-2, xvii+455 pp.
[12] M. Honma, M. Hayashi, Comparison of in vitro micronucleus and gene mutation
assay results for p53-competent versus p53-deﬁcient human lymphoblastoid cells,
Environ. Mol. Mutagen. 52 (2011) 373–384.
[13] L.S. Zhang, M. Honma, M. Hayashi, T. Suzuki, A. Matsuoka, T. Sofuni, A com-
parative study of TK6 human lymphoblastoid and L5178Y mouse lymphoma cell
lines in the in vitro micronucleus test, Mutat. Res. 347 (1995) 105–115.
[14] M.D. Fellows, M.R. O’Donovan, Etoposide, cadmium chloride, benzo[a]pyrene,
cyclophosphamide and colchicine tested in the in vitro mammalian cell micro-
nucleus test (MNvit) in the presence and absence of cytokinesis block using L5178Y
mouse lymphoma cells and 2-aminoanthracene tested in MNvit in the absence of
cytokinesis block using TK6 cells at AstraZeneca UK, in support of OECD draft Test
Guideline 487, Mutat. Res. 702 (2010) 163–170.
[15] A. Elhajouji, C. Mitomycin, 5-ﬂuoruracil, colchicine and etoposide tested in the in
vitro mammalian cell micronucleus test (MNvit) in the human lymphoblastoid cell
line TK6 at Novartis in support of OECD draft Test Guideline 487, Mutat. Res. 702
(2010) 157–162.
[16] P. Fowler, J. Whitwell, L. Jeﬀrey, J. Young, K. Smith, D. Kirkland, Cadmium
chloride, benzo[a]pyrene and cyclophosphamide tested in the in vitro mammalian
cell micronucleus test (MNvit) in the human lymphoblastoid cell line TK6 at
Covance laboratories, Harrogate UK in support of OECD draft Test Guideline 487,
Mutat. Res. 702 (2010) 171–174.
D.P. Lovell et al. Mutat Res Gen Tox En 825 (2018) 40–50
50
